Bone Biologics Inc (BBLG) - Cash per Single Share

The cash per share volume shown on this GURU.Markets chart confirms the fabless model of Bone Biologics (BBLG) with outsourced production in the US. The 1.19 mark reflects the latest data amid capital dilution risks and anticipation of clinical trial results. The financial foundation is strengthening due to unique protein technologies that enable the company to maintain pricing power for spinal implants.
Comprehensive metric breakdowns and analytics for Bone Biologics Inc (BBLG)

This metric determines the volume of net liquid assets per common share. It measures the actual capital reserve available to sustain operational activities without seeking external financing. By analyzing the cash per share indicator, an investor can see the resource base for the development of NELL-1 patents. This is critically important given the high R&D expenses and early-stage risks. This chart confirms the financial stability of Bone Biologics (BBLG).